Biomerica chooses bioaccess™ as its regulatory and market access consulting company to sell its innovative EZ Detect colorectal screening test in Colombia
[Orlando, FL, October 14, 2018] — Biomerica, Inc. (Nasdaq: BMRA) has chosen bioaccess.™ as its regulatory and market access partner to obtain marketing authorization and commercialize its innovative EZ Detect colorectal screening test in Colombia. The EZ Detect colorectal screening test is the simplest and most affordable way to help identify the early warning signs of colorectal cancer (CRC). Globally, colorectal cancer is the third most common type of cancer, making up about 10% of all cases.
The EZ Detect screening test is unique in that it offers the opportunity of cost savings for the healthcare system while saving lives. It is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of CRC The test does not require handling of stool or dietary restrictions.
The EZ Detect pad is tossed into the toilet after a bowel movement. A change in the pad's color to blue/green, which would appear within two minutes, indicates the presence of blood in the stool. The pad is then simply flushed.
CRC is a common and lethal disease. Globally, it is the third most commonly diagnosed cancer in males and the second in females, with 1.65 million new cases and almost 835,000 deaths in 2015. After prostate and breast cancer, CRC is the third most commonly diagnosed cancer in Colombia with an incidence of 15.8 cases per 100,000 inhabitants. CRC mortality rates continue to increase in many countries with more limited resources and health infrastructure, particularly in Central and South America.
Low socioeconomic status (SES) is associated with an increased risk for the development of CRC; one study estimated the CRC risk to be approximately 30 percent increased in the lowest as compared with the highest SES quintile. Potentially modifiable behaviors such as physical inactivity, unhealthy diet, smoking, and obesity are thought to account for a substantial proportion (estimates of one-third to one-half) of the socioeconomic disparity in risk of new-onset CRC. Other factors, particularly lower rates of CRC screening, also contribute substantively to SES differences in CRC risk.
Biomerica is expanding its reach to Latin America and has chosen bioaccess.™ as its regulatory and market access consulting company to obtain marketing authorization at Colombia's medical device regulatory agency (INVIMA) and to search and conduct due diligence on potential distributors.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. Biomerica's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing.
bioaccess.™ (www.bioaccessla.com) is a Florida-based clinical research organization (CRO) and market access consulting company which mission is to help innovative life science companies conduct clinical research and commercialize their innovations in Colombia and the rest of Latin America.
bioaccess.™ Press Contact:
Julio G. Martinez-Clark, CEO
Tel: +1 (954) 903-7210